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1. Introduction 
Phosphorylation of tyrosine residues is an essential biochemical reaction in many higher 
eukaryotes. One of the most important and well-studied functions of tyrosine 
phosphorylation is to convey extracellular signals to the cytoplasm and ultimately to the 
nucleus in order to control various cell functions such as proliferation, differentiation, 
migration and survival. 
The first tyrosine kinase (TK) was discovered as the tumor-inducing activity from Rous 
sarcoma virus, which is now known as v-Src (Rous, 1911). Later studies revealed that the 
oncogenic properties of v-Src was due to the loss of the regulatory mechanisms to control its 
kinase activity (Martin, 2001). These findings clearly highlight the critical importance of 
precise regulation of TK activities in order to avoid detrimental consequences to the 
homeostasis of the organisms. 
Various mechanisms are employed to control TK activities. In the Src family non-receptor 
tyrosine kinase (non-RTK), phosphorylation status of the tyrosine residue in the C-terminal 
regulatory region alters intramolecular interactions and therefore serves as a way to 
modulate kinase activity. The kinases and the phosphatases involved in this regulatory 
mechanism are, in turn, themselves under additional layers of regulation, thus, creating an 
intricate network of signal mediators to fine-tune cellular responses (Sen & Johnson, 2011). 
Incidentally, activity of a typical receptor tyrosine kinase (RTK) is regulated by ligand 
binding; RTKs alter conformation upon ligand binding and dimerize, which leads to 
transphosphorylation of critical tyrosine residues in the activation loop of the neighboring 
kinase in the cytoplasmic domain (He & Hristova). This initiates a cascade of biochemical 
reactions that activates downstream signaling pathways. 
Subcellular localization of TKs is another important determinant of their activity (Murphy 
et al., 2009). There are now abundant evidence indicating that TKs can generate different 
signals dependent on their intracellular locations. Therefore, molecules that regulate 
protein trafficking and localization constitute a critical component of signal regulatory 
mechanism. 
Covalent attachment of small proteins such as ubiquitin and small ubiquitin-like modifier 
(SUMO) to target proteins serves as a signal for various biological processing, including 
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alteration of its localization and promotion of degradation (Schulman & Harper, 2009; van 
Wijk & Timmers, 2010). This reaction is mediated by a series of biochemical reactions 
involving the E1 or activating enzyme, the E2 or conjugating enzyme and the E3 ligase. 
Human genome encodes for two E1s, thirty E2 and over one thousand E3s for the ubiquitin 
system. This pathway architecture immediately implies that the substrate specificity of the 
ubiquitin system must be achieved largely at the level of E3s. 
The Casitas B-lineage lymphoma (Cbl) family proteins are RING finger (RF)-containing 
multi-domain adaptors that function as E3 ubiquitin ligase primarily towards activated 
TKs (Thien & Langdon, 2001; Duan et al., 2004; Schmidt & Dikic, 2005). Using genetically-
engineered mouse models, we and others showed that loss of Cbl, either singly or in 
combination with another family member Cbl-b, led to the enlargement of the 
hematopoietic stem cell (HSC) compartment (Naramura et al., 2011a). Additionally, 
mutations in the CBL gene have been identified in a small but significant number of 
hematological malignancies in human, and experimental evidence proved the 
oncogenicity of mutant CBL products (Naramura et al., 2011b). All together, these 
observations strongly support that the Cbl family proteins are critical regulators of 
hematopoietic homeostasis. 
Here, we review functions of the Cbl family proteins and some of the candidate Cbl targets 
in the HSC compartment and discuss potential mechanisms of their regulation. 
2. The Cbl family proteins 
The Cbl family proteins are evolutionarily conserved signal regulators present through C. 
elegans to human (Figure 1). In mammals, this family includes Cbl (also known as c-Cbl, 
encoded by the CBL gene in human), Cbl-b (CBLB gene in human) and Cbl-c (also know as 
Cbl-3 or Cbl-SL, CBLC gene in human). Cbl was originally identified as a cellular homolog 
of a viral oncogene v-Cbl which caused leukemia and lymphoma in mice (Langdon et al., 
1989). Cbl’s involvement in signal transduction was suggested because it became 
prominently tyrosine-phosphorylated upon stimulation through various cell surface 
receptors (Donovan et al., 1994; Galisteo et al., 1995). But it was not until genetic studies in 
C. elegans identified the sli-1 gene product as a Cbl homolog that Cbl was established as a 
negative regulator of RTK signaling. 
2.1 Structure and biochemical functions of the Cbl family proteins 
All Cbl family proteins share a high degree of homology in their N-terminal regions. These 
include the tyrosine kinase binding (TKB) domain, the RF domain and the short intervening 
linker region. X-ray crystallography studies revealed that the TKB domain comprised a four-
helix bundle (4H), a calcium-binding EF hand and a variant Src homology region 2 (SH2) 
domain (Meng et al., 1999). The TKB domain mediates specific binding to cognate 
phosphotyrosine-containing motifs in activated TKs and select non-TK signal mediators 
(Lupher et al., 1996). The RF domain and the linker region together bind to E2 ubiquitin-
conjugating enzymes and both of these motifs are essential for the E3 ubiquitin ligase 
activity of the Cbl family proteins (Joazeiro et al., 1999; Levkowitz et al., 1999; Yokouchi et 
al., 1999; Zheng et al., 2000). 
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Fig. 1. Structure of the Cbl family proteins. The original oncogenic form of Cbl (v-Cbl), the 
three mammalian Cbl family proteins (Cbl, Cbl-b and Cbl-c), the short and long forms of 
Drosophila Cbl (D-CblS and D-CblL) and the C. elegans homolog (SLI-1) are shown. TKB, 
tyrosine kinase binding; 4H, four-helix bundle; EF, EF hand; SH2, Src homology region 2; L, 
linker; RF, RING finger; Y, tyrosine; UBA, ubiquitin-associated. 
Band and colleagues originally described that the Cbl TKB domain specifically 
recognized the phosphotyrosine-containing motif D(N/D)XpY, which was later refined 
as (N/D)XpY(S/T)XXP, found in several TKs such as ZAP70, epidermal growth factor 
receptor (EGFR), and Src (Lupher et al., 1997). Additional binding motifs, 
RA(V/I)XNQpY(S/T) and DpYR, were proposed in the adaptor protein APS (Hu & 
Hubbard, 2005) and the RTK c-Met (also known as hepatocyte growth factor receptor; 
Peschard et al., 2004), respectively. A recent comprehensive structural study showed that 
phosphopeptides with diverse sequences bound TKB at the same site, albeit in two 
different orientations (Ng et al., 2008). These studies collectively revealed the unique 
binding strategy for the specialized and biologically vital function of the Cbl family 
proteins and provided means to identify potential Cbl targets based on the amino acid 
sequences. 
The C-terminal half of the Cbl family proteins are more divergent. A proline-rich region 
follows the RF domain in all mammalian Cbl family proteins, but this domain is more 
prominent in Cbl and Cbl-b than in Cbl-c. Biochemical studies have demonstrated that Cbl 
interacted with SH3-domain containing proteins such as Grb2 and Nck through the proline-
rich region (Rivero-Lezcano et al., 1994; Fukazawa et al., 1995). 
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In addition to being a TK regulator, Cbl itself is subject to tyrosine phosphorylation. 
Phosphorylation at tyrosine residues 700, 731 and 774 have been extensively characterized; 
residues 700 and 774 provide docking sites for the SH2 domain-containing adaptor protein 
CrkL (Andoniou et al., 1996). Tyrosine 700 also mediates an interaction with the guanine 
nucleotide exchange factor Vav (Marengère et al., 1997). Tyrosine 731 provides a docking 
site of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) (Hunter et al., 
1999). Based on sequence homology and experimental data, tyrosine residues in the C-
terminal domain of Cbl-b are thought to share many of the same functions as those in Cbl. 
Cbl-c does not possess comparable tyrosines. 
The C-termini of Cbl and Cbl-b, but not Cbl-c, contain a conserved domain known as a 
ubiquitin-associated (UBA) domain, which is present in a variety of proteins involved in 
ubiquitin-mediated processes. Structural studies indicate that this domain is capable of 
binding ubiquitin and involved in dimerization (Kozlov et al., 2007; Peschard et al., 2007). 
2.2 Insights from genetic models 
The first critical clue into Cbl’s functions came from genetic studies in C. elegans (Yoon et al., 
1995). The vulval development in C. elegans is regulated by signals through the EGFR 
pathway. A reduction-of-function mutation in let-23 (encodes the EGFR homolog) leads to 
death of most worms, and the vulval development is incomplete in surviving worms. 
However, when loss-of-function mutations in sli-1 were introduced to this genetic 
background, worms survived and vulval development was restored. The sequence analysis 
of the sli-1 gene revealed that it encoded a protein with a high similarity to Cbl, thus 
establishing Cbl as a negative regulator of the EGFR pathway. 
Genetic studies in gene targeted mouse models provided further insights into the 
physiological roles of the Cbl family proteins in mammals. Cbl-deficient mice are viable, but 
they show recognizable changes in the hematopoietic, lymphoid, metabolic and 
reproductive systems. In contrast, effects of Cbl-b loss is mostly limited to the peripheral 
immune functions. Cbl-c expression appears to be restricted to the epithelial tissues, but no 
significant phenotypes were reported in mice deficient in Cbl-c (Table 1). 
While mice deficient in either one of the Cbl family members are viable, simultaneous loss of 
Cbl and Cbl-b is not compatible with the survival of the organism and double-deficient mice 
do not survive beyond embryonic day 10 (Naramura et al., 2002). This indicates that Cbl and 
Cbl-b play redundant and overlapping functions in critical organ systems during fetal 
development. Using the Cre-loxP-mediated conditional gene deletion approach, effects of 
Cbl, Cbl-b loss have been analyzed in the T, B and HSC compartments (Naramura et al., 
2002; Huang et al., 2006; Kitaura et al., 2007; Naramura et al., 2010). These studies 
demonstrated that, in the adaptive immune system, the Cbl family proteins are required to 
establish appropriate threshold for selection of T and B cells, and disruption of this process 
leads to autoimmune-like phenotypes in mice. 
In the hematopoietic compartment, Cbl-deficiency leads to moderate splenomegaly and 
enhanced extramedullary hematopoiesis (Murphy et al., 1998). In the bone marrow, the 
lineage-negative, Sca-1-positive, c-Kit-positive (LSK) compartment, which is highly enriched 
for HSCs, is enlarged and Cbl-deficient HSCs showed enhanced capacity to reconstitute 
myeloabrated recipient’s hematopoietic system (Rathinam et al., 2008). However, mice were 
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outwardly normal and had a normal lifespan. When both Cbl and Cbl-b are deleted in the 
HSC, however, mice succumbed to aggressive myeloproliferative disease-like leukemia 
within two to three months after birth (Naramura et al., 2010). 
 
Gene Phenotype Reference 
Cbl 
Altered T cell antigen receptor expression 
Increased tyrosine phosphorylation 
Enhanced thymic selection 
Splenomegaly and extramedullary hematopoiesis 
Decreased fertility 
Altered metabolism 
(Murphy et al., 1998; 
Naramura et al., 1998; 
Thien et al., 1999; Molero et 
al., 2004; El Chami et al., 
2005; Rathinam et al., 2008) 
Cblb 
Co-stiumlation-independent activation of 
peripheral T cells 
Predisposition to autoimmune diseases and 
inflammatory injury 
Resistance to spontaneous and transplanted tumors 
(Bachmaier et al., 2000; 
Chiang et al., 2000; 
Krawczyk et al., 2000; 
Chiang et al., 2007; Loeser 
et al., 2007; Bachmaier et 
al., 2007) 
Cblc No apparent phenotypes (Griffiths et al., 2003) 
Table 1. Phenotypes of mice deficient in the Cbl family members 
2.3 Cbl and hematological malignancies 
Because of the involvement of various RTKs in cancer, it has long been speculated that the 
Cbl family proteins may play critical roles in the initiation and/or progression of cancer. 
Oncogenic mutations in RTKs that abrogate interaction with Cbl have been reported 
(Peschard & Park, 2003), but the direct evidence supporting Cbl’s roles in cancer was not 
established until 2007. 
The vast majority of CBL mutations reported so far are associated with myeloid disorders. 
Although the first human CBL mutations were described in acute myeloid leukemia (AML) 
samples (Sargin et al., 2007; Caligiuri et al., 2007; Abbas et al., 2008), later studies 
documented a significant number of cases in myelodysplastic syndromes-myeloproliferative 
neoplasms (MDS/MPN), a heterogeneous group of myeloid disorders including the chronic 
myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML) and 
juvenile myelomonocytic leukemia (JMML) (Dunbar et al., 2008; Reindl et al., 2009; Grand et 
al., 2009; Loh et al., 2009; Sanada et al., 2009; Makishima et al., 2009; Muramatsu et al., 2010; 
Fernandes et al., 2010; Niemeyer et al., 2010). The association of CBL mutations with JMML 
is particularly thought-provoking because the pathogenesis of this rare pediatric 
hematological malignancy is closely associated with the activation of the Ras-MAPK 
signaling pathway (Loh, 2011). Among JMML patients, the activating mutations of PTPN11, 
NRAS and KRAS, and the loss of NF1, a gene encoding for a Ras GTPase-activator account 
for approximately 75 % of the total cases. Roughly half of the remainder of the cases are now 
attributed to CBL mutations. While in vitro experimental data indicate that the loss of the Cbl 
family proteins lead to prolonged Erk activation, it was never formally demonstrated 
whether Cbl can regulate Ras activity directly. 
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It is of note that most CBL mutations are either point mutation or internal deletion 
involving the linker and/or the RF regions rather than complete deletion at the CBL locus. 
As expected from domain-function analysis results, these mutant Cbl proteins lack E3 
ubiquitin ligase activity. Interestingly, in patient samples with CBL mutations, the wild-
type allele is often lost and replaced with the mutant allele by acquired uniparental 
isodisomy (aUPD). The CBLB, CBLC alleles are usually unaffected in these patients 
although mutations in these genes have been reported (Makishima et al., 2009; Makishima 
et al., 2011). All together, these clinical observations suggest that the presence of one wild-
type copy of CBL is generally sufficient to maintain the functions of Cbl in the presence of 
normal Cbl-b and Cbl-c. These findings are consistent with the data in mice expressing a 
RF-mutant Cbl from the endogenous promoter on a Cblb, Cblc wild-type background 
(Thien et al., 2005; Rathinam et al., 2010); homozygous mutant mice are perinatally lethal, 
but hemizygous mutants over the wild-type Cbl allele develop normally. However, when 
the hemizygous mutant is expressed over the Cbl-null background, mice develop 
myeloproliferative disease-like leukemia within a year. This is a striking contrast when 
compared to the rapid progression and fatality of the HSC-specific Cbl, Cbl-b double-
deficient mice (Naramura et al., 2010). These differences may reflect that the RF mutant 
and patient-derived oncogenic mutant Cbl proteins function as gain-of-function mutants 
rather than as dominant-negative inhibitors of Cbl-b (Cbl-c expression is minimal in the 
hematopoietic system). While these mutants lack E3 ubiquitin ligase activity and thus 
defective in promoting target degradation, they possess intact TKB and C-terminal 
protein-protein interaction motifs, which may enable them to form aberrant but stable 
multi-protein super-signaling complexes and activate unconventional signaling pathways. 
2.4 Potential Cbl targets in the hematopoietic system 
What, then, are the target of Cbl-dependent regulation in the HSC compartment? Because 
Cbl becomes phosphorylated upon stimulation with various cell surface receptors, it is 
conceivable that Cbl is involved in the regulation of signal transduction downstream of 
such pathways (Table 2). Among this diverse group of cell surface receptors, Kit and Flt3 
are of particular interest because both of them are RTKs expressed in HSC and known to 
perform critical functions in the HSC compartment (Masson & Rönnstrand, 2009). Colony 
stimulating factor 1 receptor (CSF1R) is known to interact with Cbl (Lee et al., 1999), but it 
is expressed primarily in more differentiated myeloid/phagocytic cells than in HSCs. 
Endothelial-specific receptor tyrosine kinase (Tek, also known as Tie2) is another RTK 
expressed in the HSC compartment (Arai et al., 2004) and therefore may interact with Cbl. 
Thrombopoietin (TPO) is indispensable for the maintenance of HSC quiescence 
(Yoshihara et al., 2007; Qian et al., 2007). Although its receptor (TPO-R, also known as 
Mpl or c-Mpl) is not an RTK, stimulation with TPO induce phosphorylation of Cbl (Sasaki 
et al., 1995), Mpl have been shown to be ubiquitinylated (Saur et al., 2010) and Cbl loss 
alters the signal transduction downstream of TPO (Rathinam et al., 2008; Naramura et al., 
2010). Therefore, Mpl may interact with Cbl indirectly. Other potential (direct as well as 
indirect) Cbl targets in the HSC compartment include the chemokine and integrin 
pathways. 
In following sections, I will discuss how these pathways may be regulated by the Cbl family 
proteins in the HSCs. 
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Antigen and other immunological receptors 
 T cell antigen receptor complex (Donovan et al., 1994; Meisner et al., 1995; 
Fukazawa et al., 1995) 
 B cell antigen receptor complex (Cory et al., 1995; Tezuka et al., 1996; 
Panchamoorthy et al., 1996) 
 Fc receptor (Marcilla et al., 1995) 
 Fc receptor (Matsuo et al., 1996; Suzuki et al., 1997) 
 
RTKs 
 Epidermal growth factor receptor (Galisteo et al., 1995) 
 Insulin receptor (Ribon & Saltiel, 1997) 
 Platelet-derived growth factor receptor (Bonita et al., 1997) 
 Kit (Wisniewski et al., 1996; Brizzi et al., 1996) 
 Flt3 (Lavagna-Sévenier et al., 1998) 
 Fibroblast growth factor receptor (Wong et al., 2002) 
 Colony stimulating factor 1 receptor (Wang et al., 1996) 
 Met (Fixman et al., 1997; Garcia-Guzman et al., 2000) 
 TrkB (McCarty & Feinstein, 1999) 
 Tie2 (Wehrle et al., 2009) 
 
Cytokine receptors 
 Interleukin 2 receptor (Gesbert et al., 1998) 
 Interleukin 3 receptor (Barber et al., 1997) 
 Interleukin 4 receptor (Ueno et al., 1998) 
 Erythropoietin receptor (Odai et al., 1995; Barber et al., 1997) 
 Mpl (Sasaki et al., 1995; Brizzi et al., 1996) 
 GM-CSF receptor (Odai et al., 1995) 
 Prolactin receptor (Hunter et al., 1997) 
 
Chemokine receptors (Chernock et al., 2001) 
 
Integrins (Ojaniemi et al., 1997; Manié et al., 1997; Meng & Lowell, 1998) 
Table 2. Partial list of potential upstream receptors for Cbl 
3. Kit 
The mouse dominant spotting mutation at the W locus was first described in the early 1900s 
(Durham, 1908). Mutations at this locus were studied extensively not only because they 
produced visible coat color changes, but also because mutant mice showed defects in 
hematopoiesis, mast cell development and gametogenesis (Russell, 1979). However, it was 
not until 1988 that the gene product at the W locus was found to encode for the cellular 
homolog of the kit oncogene which had been molecularly identified a few years earlier 
(Besmer et al., 1986; Chabot et al., 1988; Geissler et al., 1988). 
Kit is a type III RTK that shares structural similarities with platelet-derived growth factor 
receptors (PDGFRs)  and , Flt3 (also known as Flk-2, discussed below) and CSF1R. They 
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are characterized by an extracellular domain with five immunoglobulin-like domains, a 
single transmembrane domain and an intracellular tyrosine kinase domain that is split into 
two by an intervening sequence. 
HSCs are functionally defined as rare cells with the capacity to self-renew and give rise to 
all cell types of the hematopoietic lineage, including erythrocytes, granulocytes, 
monocytes, megakaryocytes and lymphocytes. No single marker specific for HSCs is 
known today. However, it is widely accepted that, in mice, most HSCs reside in a 
population of cells that express Kit and another cell surface protein Sca-1 and lack the 
expression of committed lineage markers (Ikuta & Weissman, 1992). Thus, Kit expression 
is intimately tied to HSCs. 
The ligand for Kit is called stem cell factor (SCF) and encoded by the Steel (Sl) locus. The 
phenotypes of the Sl mutant mice are in most cases similar to those of W mutant mice, 
affecting hematopoiesis, mast cell development, fertility and coat colors (Galli et al., 1993). 
Collectively, these observations firmly established the essential roles of the SCF-Kit axis in 
these biological processes. 
In the mouse embryo, hematopoietic cells are found in the blood islands in the yolk sac 
starting around embryonic day 7. Subsequently, at day 10-11 of gestation, HSCs migrate to 
the fetal liver and then to the spleen and the bone marrow, the primary hematopoietic 
organs in adult. The hematopoietic defect in W mice is detected throughout the course of 
development. Syngeneic transplantation experiments demonstrated that the defect exerted 
by W mutations was intrinsic to hematopoietic cells. The hematopoietic microenvironment 
in these animals are not affected and able to support hematopoiesis of normal donor-
derived cells (Russell, 1979). 
Kit activity is regulated at various levels. Ligand-receptor engagement of Kit initiates 
receptor dimerization and subsequent activation of its TK activity. Extensive biochemical 
studies have mapped intracellular phosphorylated tyrosine residues and their interacting 
proteins. These include Src family TKs, phosphatases such as SHP1 and SHP2, 
phospholipase C, p85 subunit of phosphoinositide-3 kinase, (p85(PI3K)) and adaptor 
proteins such as Grb2 and APS (Lennartsson et al., 2005). 
Cbl becomes phosphorylated when Kit-expressing cells are stimulated with SCF 
(Wisniewski et al., 1996). Earlier studies suggested that Cbl interacted with Kit indirectly 
through Grb2 (Brizzi et al., 1996), CrkL and p85(PI3K) (Sattler et al., 1997), and APS 
(Wollberg et al., 2003). More recent data suggest that Cbl binds to Kit directly at tyrosine 
568, which is located in the juxtamembrane domain, and tyrosine 936, which is located in the 
carboxyterminal tail, ubiquitinylate Kit and target them for degradation (Masson et al., 
2006). Both Cbl and Cbl-b function similarly towards Kit (Zeng et al., 2005). Hematopoietic 
cells deficient in Cbl functions are hypersensitive to stimulations through Kit (Naramura et 
al., 2010; Rathinam et al., 2010). These data all together strongly support that Kit may be one 
of the physiological targets of Cbl proteins in the HSC compartment. 
Structurally, sequences surrounding tyrosine 568 partially conform to the canonical 
Cbl(TKB) recognition sequence while those around tyrosine 936 do not. Further analyses 
into the mechanisms of binding between Cbl and Kit may reveal novel molecular 
interactions that remained unknown so far. 
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4. Flt3 
Flt3, another member of the type III RTKs, was originally identified by two separate groups 
through homology screening for TKs (Matthews et al., 1991; Rosnet et al., 1991). Its 
expression is detected in placenta, gonads, brain and hematopoietic cells, but its role outside 
of the hematopoietic system is not clear at present. Ligand for Flt3 (Flt3 ligand; FL) was 
identified a few years later and its transcript is expressed in wide range of both fetal and 
adult tissues (Lyman et al., 1993; Hannum et al., 1994). 
Roles of Flt3 in HSCs appear to vary among species and also dependent upon 
developmental stages. The most primitive self-renewing HSCs with long-term 
reconstituting potential (LT-HSCs) are not found within Flt3+ LSK cells in adult mouse bone 
marrow while the same biological activity was detected in both Flt3+ and Flt3- populations 
in fetal liver (Adolfsson et al., 2001; Christensen & Weissman, 2001). Notably, human HSCs 
with multi-lineage reconstituting activity are Flt3+ (Sitnicka et al., 2003). Flt3 deficient mice 
are viable and fertile, but show defects in B lymphocyte progenitors and dendritic cell 
generation (Mackarehtschian et al., 1995). The role of the FL-Flt3 axis in HSC maintenance 
and expansion remains controversial. Mackarehtschian et al. originally reported that Flt3-
deficient bone marrow cells showed defects in lymphoid and myeloid reconstitution upon 
transplanting into myeloablated hosts (Mackarehtschian et al., 1995), while a more recent 
report by Buza-Vidas et al. concluded that Flt3 and FL were dispensable for maintenance 
and posttransplantation expansion of mouse HSCs (Buza-Vidas et al., 2009). Partly based on 
the phenotypes of Flt3 and FL deficient mice, models were proposed that Flt3 might 
function in the lineage restriction process from HSCs to lymphoid progenitors (Luc et al., 
2007). However, in human, activating mutations in the FLT3 gene, either in the form of 
internal tandem duplication (ITD) mutation in the juxtamembrane domain or point 
mutations in the kinase domain, are more frequently associated with myeloid malignancies 
rather than with lymphoid malignancies (Stirewalt & Radich, 2003). Clearly, the roles of Flt3 
in the normal and pathological hematopoiesis need to be further delineated. 
Cbl becomes tyrosine phosphorylated upon Flt3 engagement (Lavagna-Sévenier et al., 1998). 
It has been shown to physically interact with Flt3, and overexpression of an E3 ligase-
defective mutant Cbl inhibited FL-induced Flt3 ubiquitylation and internalization, 
indicating involvement of Cbl in Flt3 signaling regulation (Sargin et al., 2007). Mice 
expressing a RF mutant Cbl from its endogenous locus are hypersensitive to FL stimulation 
(Rathinam et al., 2010), and we confirmed a similar phenotype in mouse bone marrow cells 
deficient in both Cbl and Cbl-b (Naramura, manuscript in preparation). Furthermore, 
deletion of FL blocks leukemia development in Cbl RING finger mutant mice (Rathinam et 
al., 2010). 
Nevertheless, the mode of interaction between Cbl and Flt3 has not been clarified. Direct 
binding between Cbl and Flt3 has not been demonstrated. The sequences surrounding 
tyrosine 589 partially conform to the canonical Cbl(TKB) recognition sequence, and this 
region shares a very high homology to the sequences surrounding tyrosine 568 (a candidate 
Cbl binding site) in Kit. Notably, this is also the region frequently affected by ITD 
mutations. Alternatively, or in addition to the direct binding, because Flt3 is known to 
interact with Grb2 (Dosil et al., 1993; Zhang et al., 1999), a Cbl-binding adaptor protein, Cbl-
Flt3 interaction may be mediated through this adaptor protein. 
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5. Other potential targets 
As is clear from the list of potential Cbl upstream receptors, Kit and Flt3 may not be the only 
targets of Cbl-dependent regulation in HSCs. Although pathways other than Kit or Flt3 have 
not been as carefully examined in relation to Cbl, existing evidences suggest that following 
pathways may be regulated by the Cbl family proteins either directly or indirectly. 
5.1 Tek 
Tie2, encoded by the TEK gene, is an RTK expressed predominantly on endothelial cells, but 
they also provide crucial functions in the maintenance of quiescence and self-renewal 
capacity of the HSCs (Arai et al., 2004). The interaction between Tie2 and angiopoietin-1 
(Ang-1), its ligand, has been shown to promote ubiquinylation of Tie2 by Cbl and receptor 
internalization (Wehrle et al., 2009). Structurally, the cytoplasmic domain of Tie2 does not 
contain any tyrosine residues that match the canonical Cbl(TKB) recognition sequence. 
However, activated Tie2 is known to bind Grb2 (Huang et al., 1995), thus may interact with 
Cbl indirectly through this adaptor. 
5.2 Cytokine receptors 
Cytokines such as hematopoietic growth factors and interleukins play essential roles in 
hematopoiesis. Cbl becomes tyrosine phosphorylated upon stimulation through various 
cytokine receptors (Table 2), and hematopoietic cells deficient in Cbl activity show enhanced 
sensitivity to cytokines (Rathinam et al., 2008; Sanada et al., 2009; Naramura et al., 2010). 
Receptors for these factors do not possess cytoplasmic tyrosine kinases but they activate the 
Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway 
(Yoshimura, 2009). Ligand binding induces receptor oligomerization, which activate 
associated JAK kinases and they, in turn, phosphorylate the receptor cytoplasmic domains 
and create binding sites for SH2-containing proteins. 
There is no solid experimental evidence supporting the direct interaction between the 
JAK/STAT pathway and Cbl. Activation of the JAK/STAT pathway induces the expression 
of Suppressor of Cytokine Signaling (SOCS) family proteins, which function as E3 ubiquitin 
ligases for this pathway. 
In addition to the JAK/STAT pathway, ligand binding to cytokine receptors activate the 
Ras-MAPK pathway through adaptor proteins such as APS and Grb2. Activation of this 
pathway is required for cell proliferation. As discussed above, these adaptor proteins are 
know to interact with Cbl, providing a potential link between the cytokine pathway and the 
Cbl family proteins. 
6. Conclusion 
In spite of its original identification as a cellular homolog of a viral oncogene, 
pathophysiological roles of the Cbl family proteins remained unclear for some time. Genetic 
studies in model organisms as well as identification of CBL mutations in patient-derived 
specimen played crucial roles in deciphering their essential functions as regulators of HSC 
homeostasis. Combined with molecular/biochemical information gathered over the last two 
decades, we now appreciate the complexity of the regulatory pathways surrounding the Cbl 
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family proteins. While the primary focus of studies in the last ten years has been on Cbl’s E3 
ubiquitin ligase functions towards phosphotyrosine motif-containing targets, observations 
in cells expressing mutant Cbl proteins began to challenge this relatively-simplistic 
viewpoint. Further studies into this multifaceted protein family may uncover opportunities 
for novel diagnostics and therapeutics. 
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